Home | Welcome to Contract Pharma   
Last Updated Sunday, May 24 2015


Financial Report: Akorn

Published February 26, 2013

4Q Revenues: $71.5 million (+68%)

4Q Earnings: $8.8 million  (+54%)

FY Revenues: $256.2 million (+87%)

FY Earnings: $35.4 million (-18%)

Comments: Growth in the quarter and FY was driven by the Lundbeck and Kilitch acquisitions, the sale of newly approved and re-launched products, and growth of established products, offset by decreases in the U.S. contract services business.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On